Advantages and disadvantages of statin treatment in the elderly for the secondary prevention of CHD
| Age | |||
|---|---|---|---|
| 40–80 years MRC/BHF20 | 70–80 years MRC/BHF20 | 70–82 years PROSPER21 | |
| MRC/BHF, Medical Research Council/British Heart Foundation; PROSPER, pravastatin in elderly individuals at risk of vascular disease. | |||
| Advantages | |||
| Change in coronary events | −27% | −20% | −19% |
| Change in stroke events | −25% | – | +3% |
| Disadvantages | |||
| Development of myopathy | 0.06% | – | <0.01% |
| Development of disturbed liver function | 0.18% | – | <0.01% |
| Increase in cancer incidence | No | – | +25% |